Kornimate/medical-research-clean huggingface dataset:
treatment of social phobia with cognitive bias modification

Conditions: Social Phobia

Summary: the purpose of this study is to determine whether different internet-based treatment programs, consisting of cognitive bias modification, reduce symptoms of social phobia among a population diagnosed with this disorder.

previous studies have shown that individuals with social phobia have attention biases, often focusing on aversive stimuli or avoiding aversive stimuli. computerized training programs have been developed to implicitly direct the users attention towards a neutral, non-threatening stimuli. in this study, such a program will be provided to 128 participants that meet the diagnostic criteria for social phobia. it will be compared with a program that implicitly directs the users' attention towards threatening cues. pre/post-measurements will be compared. participants will be randomized to one of three groups, receiving one of the two variants of the cognitive bias modification program or a control training.

Eligibility criteria:
inclusion criteria: * written informed consent provided * diagnosed social phobia (according to dsm-iv criteria) * access to computer with internet connection, and printer exclusion criteria: * severe depression (and/or suicidal behavior) * addiction and/or abuse * suffer from other severe psychiatric condition (e.g. psychosis) * non-stable use of medication * undergoing other, parallel psychological treatment

Keywords: social phobia social anxiety cognitive bias modification
application of linkage analysis in the identification of novel hereditary factors in familial aneurysms

Conditions: Familial Thoracic Aortic Aneurysm and Aortic Dissection

Summary: the aim of this study is to describe the effectiveness of the application of linkage analysis, compared to the standard procedures currently provided by the italian nhs, in the identification of thoracic aortic aneurysms and dissection (taad) transmission markers in individuals with familial taad.

according to current guidelines, it is important to screen first-degree relatives of patients with familial thoracic aortic aneurysm and dissection (ftaad) using imaging techniques in order to detect any undiagnosed or asymptomatic cases. the current diagnostic methods for ftaad involve clinical and instrumental diagnosis. in addition to these methods, genetic analysis through dna testing, using a blood sample has become an essential tool. the use of massive parallel sequencing (ngs) of multiple genes or the entire exome (whole exome sequencing - wes) is considered the gold standard for genetic diagnosis of ftaad. however, it should be noted that linkage studies are not currently included in the diagnostic protocols of the italian national health system, although they may be helpful in complex familial cases where dna sequencing has not provided conclusive evidence.

Eligibility criteria:
inclusion criteria: * patients with ascending thoracic aortic aneurysms in the absence of a mutation identified by wes * subjects with small and medium artery aneurysms in the absence of a mutation identified by wes * relatives of individuals with ascending thoracic aortic aneurysms in the absence of a mutation identified by wes * relatives of individuals with ascending thoracic aortic aneurysms in the absence of a mutation identified by wes * signed informed consent exclusion criteria: * subjects wit syndromic ftaad with wes identified gene mutation * subjects wit non-syndromic ftaad with wes identified gene mutation

Keywords: familial thoracic aortic aneurysm and dissection linkage analysis biomarkers
three dimensional (3d) ultrasound in predicting response to breast cancer therapies

Conditions: Breast Cancers

Summary: the purpose of this study is to determine how well changes can be determined in malignant masses from ultrasound scans.

to evaluate the proportions of correct diagnosis of response to breast cancer therapies for localized breast cancer by ultrasound. to develop a model based on patient characteristics, physical exam, and radiologic studies which will predict the possibility that a patient has had a complete pathological response to chemotherapy neoadjuvant therapy.

Eligibility criteria:
inclusion criteria: * newly diagnosed breast cancer prior to receiving breast cancer therapy. * diagnosis of breast cancer must be confirmed by fine needle aspiration or core biopsy. exclusion criteria: * poorly controlled diabetes. * contralateral mastectomy prior to neoadjuvant chemotherapy. * not a surgical candidate. * no previous axillary lymph node dissection.
coronary angiography therapeutic virtual reality

Conditions: Virtual Reality; Atherosclerosis; Coronary Artery Disease; Anxiety; Pain, Acute; Vasospasm;Peripheral

Summary: the cath-vr study will investigate the effect of virtual reality (vr) on patient pain, anxiety, and radial artery vasospasm during coronary angiography. our hypothesis is that the use of vr will decrease patient anxiety and pain via validated scoring systems, as well as show a low rate of vasospasm of the radial artery. in addition, we hypothesize that the amount of opioid and benzodiazepine medications utilized for procedural sedation will be lower in the intervention arm. vr has gained recent attraction as an alternative or adjunctive treatment option for pain, but its effect on reducing procedural sedation has not been studied. we propose a single center, randomized control pilot study to further investigate. the patient population will include adults older than 18 years who present for outpatient diagnostic coronary angiography.

we plan to conduct a prospective, unblinded, randomized control pilot study to test our hypothesis that the use of vr will decrease patient anxiety and pain via validated scoring systems, as well as show a low rate of vasospasm of the radial artery. patients will be eligible if they are greater than 18 years of age and undergoing an elective outpatient coronary angiogram with or without percutaneous intervention. exclusion criteria will include patients with claustrophobia, seizure disorder, motion sickness, stroke within the past year, dementia, nausea, isolation status for infection control or those who do not wish to participate. outpatients undergoing routine coronary angiography with or without possible percutaneous intervention will be screened for enrollment criteria. those who agree to participate will be randomized to either the intervention or control arm. those randomized to the intervention arm and agree to participate in the study will wear a vr headset and headphones; those who are randomized to the control will receive the standard of care, which is moderate sedation for patient anxiolysis and pain control during the case. in both arms, the patient and operator will still be able to communicate verbally if needed to assess for pain, to ask questions, or to ask for anxiolytic or analgesic medications as needed. the procedure will be completed when vascular sheaths are just about to be removed.

Eligibility criteria:
inclusion criteria: - age greater than or equal to 18 years undergoing diagnostic coronary angiogram exclusion criteria: * claustrophobia * seizure disorder * motion sickness * stroke within the past year * dementia * nausea * isolation status for infection control * do not wish to participate.

Keywords: virtual reality anxiety vasospasm pain coronary artery angiography angiogram vr
role of topical vancomycin in reducing infections in hip and knee arthroplasty

Conditions: Osteoarthritis, Knee; Osteoarthritis, Hip; Rheumatoid Arthritis; Avascular Necrosis of Hip

Summary: the study is designed to assess the efficacy of vancomycin powder and dilute povidone-iodine lavage (vip protocol) in reducing the pji after primary total hip arthroplasty (tha) and total knee arthroplasty (tka). we hypothesized that vip protocol provides superior reduction of periprosthetic joint infection (pji) rates after primary tha and tka compared with diluted povidone-iodine (pi) protocol.

patients who undergo primary hip or knee arthroplasty, before closure 0,35% povidone-iodine (17,5ml in 500 ml saline) solution lavage left for 3 minutes following final implantation. patients drawn by random numbers calculator will be administered with 1.0 g vancomycin powder into the wound around the prosthesis and no suction will be used.

Eligibility criteria:
inclusion criteria: * undergoing tha or tka as a result of osteoarthritis or rheumatoid arthritis, can understand and comply with the study protocol, have signed the informed consent document at screening exclusion criteria: * patients referred to the hospital in order to undergo tha or tka due to different reason than osteoarthritis, rheumatoid arthritis or avascular necrosis of the femoral head, such as: failed femoral neck fractures, displaced acetabular fractures or revision acetabular fractures, revision knee or hip arthroplasty
oregon prep at home study

Conditions: HIV/AIDS

Summary: this demonstration study will evaluate the real-world implementation of long-acting cabotegravir (cab-la) for hiv pre-exposure prevention (prep) through a partnership between the ohsu tele-prep program (tpp) and the ohsu home infusion pharmacy (hip). the study will perform a formative evaluation of the tpp/hip partnership to determine its merit and worth, with revisions made as needed to improve the program, which is reflective of a real-world program rollout. the study is observational, and there is no comparison group. the primary objective is to evaluate adherence to cab-la by both urban and rural participants using the tpp/hip partnership. the goals of the study are improve the tpp/hip program itself with attention to reducing geographic disparities, and to disseminate best practices and lessons learned to the broader hiv prevention community.


Eligibility criteria:
inclusion criteria: * residence in oregon * english or spanish spoken and written language ability * clinical eligibility for prep with cab-la including hiv-negative serostatus * access to stable internet * access to a clean, safe location that is appropriate for home administration exclusion criteria: * clinical ineligibility for prep with cab-la including hiv-positive serostatus, injection drug use as only hiv risk factor, or clinical contraindication (such as a hypersensitivity reaction to cab-la or use of a contraindicated medication). * uninsured * payer does not cover hip services * pregnancy * residence outside of the home infusion program's catchment area * incarceration * decisional impairment

Keywords: hiv prevention prep telemedicine home infusion pharmacy long-acting cabotegravir
evaluating a physical activity index for assessment and counseling for breast and colon cancer survivors

Conditions: Breast Cancer; Colon Cancer

Summary: the purpose of this research study is to determine whether using the physical activity index screener, exercise coaching, and self-monitoring will increase physical activity and reduce time spent sitting or being inactive in patients who had breast or colon cancer.

to assess the feasibility (participation rate, adherence, and retention) of the physical activity index (pai) intervention in breast and colon cancer survivors supported by exercise coaching and self-monitoring tools.

Eligibility criteria:
inclusion criteria: * survivors of breast or colon cancer (stages 0-iii) diagnosed within the last three years prior to enrollment. * completed primary treatment (surgery, chemotherapy, and/or radiation) at least 3 months prior to enrollment. * at least 50 years of age or older. * access to internet or cellular plan for video calls. * being willing and able to comply with the approved protocol and able to sign an irb-approved informed consent document directly, remotely or via electronic consent. * able to read and speak english exclusion criteria: * participants with metastatic disease. * participants with recurrence or diagnosis of a different cancer. * participants receiving treatment other than maintenance therapy for their primary cancer (breast or colon). * participants has prior conditions that contraindicate exercise as determined by treating physician. * participants has gross cognitive impairment as determined by treating physician.

Keywords: physical activity exercise coaching
optimal a1c control in post liver or combined liver and kidney transplant recipients who have diabetes mellitus

Conditions: Diabetes; Liver Transplant; Complications; Kidney Transplant Failure

Summary: major cardiovascular events are greatest in liver transplant recipients with sustained post-transplantation diabetes1. however, the optimal a1c target after transplantation has not been studied. the objective is to understand the optimal a1c target post liver and combined liver and kidney transplant. strict a1c control will improve mortality and cardiovascular risk post liver and combined liver and kidney transplant and improve complications post liver and combined liver and kidney transplant.

major cardiovascular events are greatest in liver transplant recipients with sustained post-transplantation diabetes. however, the optimal a1c target after transplantation has not been studied. the objective is to understand the optimal a1c target post liver and combined liver and kidney transplant. strict a1c control will improve mortality and cardiovascular risk post liver and combined liver and kidney transplant and improve complications post liver and combined liver and kidney transplant. strict blood sugar control in non-transplant patients with diabetes mellitus has shown unfavorable results in previous studies. however, no optimal a1c level has been studied in liver and combined liver and kidney transplant patients. furthermore, guidelines for a1c target post-transplant are of expert opinion. the primary objective is to assess the impact of hemoglobin a1c on all-cause mortality among patients with diabetes mellitus undergoing liver or combined liver and kidney transplantation between 2008 to 2018. the second objective is to assess the impact of hemoglobin a1c on complications post liver or combined liver and kidney transplantation.

Eligibility criteria:
inclusion criteria: * all patients 18 years old or older in the united states with diabetes undergoing or post liver and combined liver and kidney transplant from january 2008 to december 2018. exclusion criteria: * \<18 years old

Keywords: hemoglobin a1c
a study to describe the use of tofacitinib after use of rituximab in patients with rheumatoid arthritis in a real-world setting

Conditions: Arthritis, Rheumatoid

Summary: this study is to characterize the use of tofacitinib after use of rituximab in patients with rheumatoid arthritis in a real-world setting.


Eligibility criteria:
inclusion criteria: * enrolled in the corevitas ra registry and initiated tofacitinib on or after november 2012. * initiate tofacitinib (defined as first ever use of tofacitinib) at registry enrollment visit or at a registry follow-up visit after november 2012 * have prior use of rituximab * have cdai measured at baseline and appropriate follow-up visit. exclusion criteria: * there are no exclusion criteria for this study
use of ctdna for monitoring of stage iii colorectal cancer

Conditions: Stage III Colorectal Cancer

Summary: this observational study will evaluate circulating tumor dna (ctdna) as a prognostic marker and as a monitor of disease recurrence in stage iii colorectal cancer (crc).

circulating tumor dna (ctdna) are small fragments of nucleic acid that originate from apoptotic or necrotic tumor cell turnover. characteristic of the malignant process, ctdna can be assessed in plasma and offers the potential of a sensitive and specific biomarker for prognostic information on disease-free or overall survival, and predictive information on chemotherapy resistance and probability of lack of response to treatment. this study will evaluate ctdna as a prognostic marker and as a monitor of disease recurrence in stage iii colorectal cancer (crc). we will recruit newly diagnosed stage iii crc patients, determine their tumor mutational profile, and systematically collect high volume (\>10 ml), serial plasma specimens every 3 months for up to 3 years and every 6 months in years 4-5 for ctdna and concurrent carcinoembryonic antigen (cea) measurement. clinical outcome and survival will be tracked. the resulting data will permit assessment of ctdna as a prognostic marker for disease-free and overall survival and as a monitor of disease recurrence in comparison with cea.

Eligibility criteria:
inclusion criteria: * men and women with crc stage iii a, b, or c * age ≥18 years * willingness to provide blood samples for research purposes * ability to understand written informed consent document, and written informed consent provided exclusion criteria: * blood sampling would compromise patients overall health such as presence of severe anemia * unable to give informed consent

Keywords: colorectal cancer
improving the reproductive health of families

Conditions: Reproductive Health

Summary: this research will assess the effectiveness of a parent- and an adolescent- intervention in lowering risk of stis, hiv, and unintended pregnancies among batswana youth.

youth in botswana face extraordinary challenges as they transition through adolescence. high rates of teen pregnancy force girls to drop out of school after which few resume their education. sexually transmitted infections (stis) are prevalent and the country has the 3rd highest human immunodeficiency virus (hiv) prevalence in the world, with incidence increasing rapidly among adolescents 15-19, peaking at 40.2% hiv seroprevalence at ages 30-34. traditional methods for sex education through village initiation schools are no longer available and parents are not comfortable with discussions addressing reproductive health within the family. as a result, adolescents have no conduit to educate them about healthy sexual development. this study will recruit 456 families, ½ with a male and ½ with a female adolescent. families will be randomized to one of three intervention arms. parents will participate in families matter 2! (fm2) and adolescents in living as a safer teen (last), both evidence-based interventions that were adapted and pilot tested in botswana during an earlier r34 award. in arm 1, the parent will participate in fm2 immediately and the youth will participate in last six months later. in arm 2, both the parent and youth will participant in their respective interventions simultaneously. in arm 3, the comparison condition, participants will be offered the interventions immediately after the final assessment. each adolescent and parent will complete assessments in english or setswana at baseline, post-intervention, and 6- and 12-month follow-ups. results from a pilot trial of the adapted interventions suggest that these interventions may result in improved family communications, child management skills, knowledge of sexual development, more favorable attitudes toward contraception, less tolerance for intergenerational transactional sex, greater rejection of gender violence, and lower rates of sexual risk behavior by both parents and adolescents. it is further anticipated that youths who are abstinent upon entering the intervention will delay sexual debut to a greater extent than youth in the comparison arm. this proposed study addresses the highest priority in botswana's current national strategic plan: preventing early pregnancy, stis and hiv in adolescents. if the proposed randomized controlled trial (rct) provides strong evidence of effectiveness, the investigators will work with the ministries of education, health, youth \& culture and the office of the president to disseminate the intervention throughout botswana.

Eligibility criteria:
inclusion criteria: * adolescent 13-18 in or near gaborone botswana and parent/guardian exclusion criteria: * none

Keywords: hiv sti unplanned pregnancy reproductive health of families adolescents
exercise in patients admitted with recently decompensated heart failure

Conditions: Decompensated Heart Failure; Functional Cardiac Disorder

Summary: an aerobic physical exercise protocol will be applied to patients admitted in ward due to decompensated heart failure, in order to validate the efficacy and safety of physical exercise in this phase of clinical stabilization, through the said training protocol - eric program.

with the objective of validating the efficacy and safety of physical exercise as a therapeutic resource in patients admitted for decompensated heart failure; will be applied, by rehabilitation nurses, a protocol of physical exercise, with increasing levels of intensity. patients who meet the inclusion criteria will be randomized through an online program (randomizer.org) and the eric protocol will be applied to the test group. the control group will be implemented the usual care of rehabilitation nursing. the eric protocol comprises 5 levels of intensity, as following shown: stage 1 - respiratory and calisthenic exercises (5-10 minutes) stage 2 - pedal for 5-10 minutes stage 3 - aerobic training: walking on the corridor for 5-10 minutes stage 4 - aerobic training: walking on the corridor for 10-15 minutes stage 5 - aerobic training: walking on the corridor for 15 minutes + climbing stairs for 5 minutes all patients will be monitored and followed up by a rehabilitation nurse while they are doing the exercise. the investigator decides, depending on the patient's performance and clinical conditions, the form of progression in the program, but it is mandatory to follow the previously defined levels of intensity. patients in the test group may start the program only on stage i or ii according to clinical criteria. at admission of the patients (test group and control group) clinical and sociodemographic parameters are evaluated, as well as data related to barthel's indices and london chest of activities of daily living (lcadl). at the discharge date, the barthel index and the lcadl scale will also be evaluated, as well as the 6-minute walking test.

Eligibility criteria:
inclusion criteria: * admission diagnosis of decompensated heart failure * more than 18 years old * capacity to provide informed consent exclusion criteria: * osteoarticular pathology that impedes the performance of the exercise * existence of inotropic infusions * dysrhythmia or precordial pain in the last 24 hours * acute pulmonary edema in the last 12 hours * systolic blood pressure greater than 180millimetre of mercury (mmhg) or less than 80mmhg (except in cases where this is the baseline value for the patient) * need for oxygen at a rate greater than 3 /min * glycemic decompensation in the last 12 hours

Keywords: exercise rehabilitation nursing functional capacity heart failure